Assignee
SCRIBE THERAPEUTICS INC
US·11 granted patents·20 pending applications·39 citations·filing 2020–2024
Top patents by PatentIndex Score
31 records- 0194US11560555B2Engineered proteinsSCRIBE THERAPEUTICS INC·Filed 2021·Granted Jan 24, 2023·15 cites·25 claims
- 0293US12084692B2Guide scaffoldsSCRIBE THERAPEUTICS INC·Filed 2022·Granted Sep 10, 2024·5 cites·38 claims
- 0393US11535835B1Compositions and methods for the targeting of rhodopsinSCRIBE THERAPEUTICS INC·Filed 2021·Granted Dec 27, 2022·7 cites·26 claims
- 0492US11613742B2Compositions and methods for the targeting of SOD1SCRIBE THERAPEUTICS INC·Filed 2021·Granted Mar 28, 2023·4 cites·25 claims
- 0591US12163125B2Engineered class 2 type V CRISPR systemsSCRIBE THERAPEUTICS INC·Filed 2022·Granted Dec 10, 2024·5 cites·28 claims
- 0688US11976277B2Particle delivery systemsSCRIBE THERAPEUTICS INC·Filed 2023·Granted May 7, 2024·3 cites·23 claims
- 0785US12559743B2Engineered guide scaffoldsSCRIBE THERAPEUTICS INC·Filed 2024·Granted Feb 24, 2026·0 cites·28 claims
- 0885US2025136962A1Catalytically dead engineered proteinsSCRIBE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0984US2025043262A1Gene editing pairsSCRIBE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1080US2025011756A1Methods of editing with engineered class 2 type v crispr systemsSCRIBE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1175US12553037B2Engineered class 2, type V repressor systemsSCRIBE THERAPEUTICS INC·Filed 2024·Granted Feb 17, 2026·0 cites·26 claims
- 1274US2024101984A1Compositions and methods for the targeting of sod1SCRIBE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1374US2022220508A1Engineered casx systemsSCRIBE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1471US12551573B2Compositions and methods for the targeting of PCSK9SCRIBE THERAPEUTICS INC·Filed 2023·Granted Feb 17, 2026·0 cites·22 claims
- 1570US2024026385A1Engineered class 2 type v crispr systemsSCRIBE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1669US12594349B2Compositions and methods for the targeting of PCSK9SCRIBE THERAPEUTICS INC·Filed 2023·Granted Apr 7, 2026·0 cites·24 claims
- 1764US2024392271A1Engineered casx repressor systemsSCRIBE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1864US2024360474A1Self-inactivating vectors for gene editingSCRIBE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1963US2022348925A1Compositions and methods for the targeting of sod1SCRIBE THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2061US2025361525A1Aav vectors for gene editingSCRIBE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2160US2024309344A1COMPOSITIONS AND METHODS FOR THE TARGETING OF C9orf72SCRIBE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2260US2023033866A1Compositions and methods for the targeting of rhodopsinSCRIBE THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2359US2023032369A1Compositions and methods for the targeting of httSCRIBE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2459US2025333767A1Engineered class 2 type v crispr systemsSCRIBE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2557US2024207196A1Compositions of glycoprotein particlesSCRIBE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2657US2022177872A1Deep mutational evolution of biomoleculesSCRIBE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2757US2024026386A1Compositions and methods for the targeting of bcl11aSCRIBE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2856US12551560B2Compositions and methods for use in immunotherapySCRIBE THERAPEUTICS INC·Filed 2020·Granted Feb 17, 2026·0 cites·37 claims
- 2955US2024100185A1Compositions and methods for the targeting of ptbp1SCRIBE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3053US2023167424A1Compositions and methods for the targeting of pcsk9SCRIBE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3152US2024033377A1Aav vectors for gene editingSCRIBE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →